Videos

Dr. Kim shares her insights on new investigational therapies for metastatic ALK+ NSCLC that she's particularly excited about.

Dr. Garon discusses the circumstances that might lead him to switch a patient with ALK+ NSCLC from another ALK inhibitor to lorlatinib.

Additional results from the phase 3 NIAGARA trial showed improved event-free survival and overall survival with durvalumab/gemcitabine/cisplatin in MIBC.

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.

Panelists discuss, when evaluating chimeric antigen receptor T-cell (CAR T) therapy for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), how key considerations include the patient’s fitness, disease burden, prior treatment response, and timing of referral. The limitations of traditional salvage therapy, with historically poor outcomes, must be weighed against CAR T’s potential for durable remissions despite its risks and complexities.

Panelists discuss how the diffuse large B-cell lymphoma (DLBCL) treatment landscape has seen significant evolution with the integration of targeted therapies and chimeric antigen receptor T-cell treatments, supplementing traditional R-CHOP. However, early relapsed/refractory cases remain challenging due to complex tumor biology and resistance mechanisms. This underscores the need for better up-front risk stratification tools and biomarker-driven treatment selection.

Experts discuss frontline treatment options for advanced upper gastric adenocarcinoma, molecular testing methods, challenges encountered, and how test results influence the choice of systemic therapy for patients.

Experts discuss Robert’s journey with HER2- upper gastrointestinal (GI) cancer, highlighting key treatment approaches and challenges.

Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.

Experts discuss the 3-year follow-up from the phase 3 TRANSFORM study, providing an overview of the study and key efficacy data.

Experts provide a brief overview of the current treatment landscape and unmet needs in relapsed/refractory (R/R) large B-cell lymphoma.

Panelists discuss how future analyses in advanced gastric cancer should assess long-term survival, real-world outcomes, biomarkers for response, resistance mechanisms, and patient selection for nivolumab plus chemotherapy. Evaluating these factors will optimize treatment strategies and confirm its role across diverse populations.

Dr. Kim discusses her approach to selecting the next treatment for patients with ALK+ NSCLC who progress on lorlatinib, including the key factors she considers in making this decision.

Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.

Dr. Garon explains his approach to choosing between different ALK inhibitors for ALK+ NSCLC, outlining the factors that guide his selection and when he might prefer alectinib, lorlatinib, or brigatinib.

Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.

The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.

Care for brain metastases is constantly evolving, and now, physicians can use targeted systemic therapies as well as more focal radiation to treat them.

Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.

Panelists discuss how emerging treatments, digital health tools, and enhanced care coordination could streamline disease management and improve quality of life while identifying opportunities to strengthen provider communication and access to resources.

Panelists discuss how their lived experiences and insights as patients should inform research priorities, treatment development, and care delivery improvements while sharing hopes for a future cure that would eliminate ongoing disease management needs and allow greater life flexibility.

Panelists discuss how they maintain treatment adherence through digital health apps, calendar reminders, and symptom journals while working closely with their care teams to address uncertainties and make informed decisions about therapy adjustments, with crucial support from caregivers who help track appointments and provide emotional encouragement throughout their chronic care journey.

Panelists discuss how they navigated initial treatment confusion by seeking clarification from healthcare providers, consulting patient resources, and connecting with support groups to better understand their care journey.

There were no new safety signals with cemiplimab plus chemotherapy in the phase 2 EPIC-A trial, Challapalli stated.

With Kevin Kalinsky, MD, the Oncology Brothers discuss sequencing treatment for endocrine-resistant diseases, which involves using a strategic approach to combat resistance to hormonal therapies. It includes combining therapies such as CDK4/6 inhibitors, mTOR inhibitors, and chemotherapy, aiming to overcome resistance and improve patient outcomes.

With Kevin Kalinsky, MD, the Oncology Brothers discuss metastatic breast cancer treatment, including hormone therapy, targeted therapy, chemotherapy, immunotherapy, and radiation. Options depend on cancer type, location, and patient health. The goal is to manage symptoms, slow progression, and improve quality of life.

With Kevin Kalinsky, MD, the Oncology Brothers discuss the treatment of locally advanced disease, which typically involves a multimodal approach, including surgery, radiation, and systemic therapies such as chemotherapy, immunotherapy, or targeted agents. The goal is to control tumor spread, reduce recurrence risk, and improve survival outcomes.

With Kevin Kalinsky, MD, the Oncology Brothers discuss hormone receptor–positive (HR+) breast cancer treatment, which targets HR+ tumors using hormone therapy (eg, tamoxifen, aromatase inhibitors), chemotherapy, targeted therapy (eg, CDK4/6 inhibitors), or sometimes surgery or radiation, depending on cancer stage and risk factors.

Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.